title: Diestrus administration of oxytocin prolongs luteal maintenance and reduces plasma PGFM concentrations and endometrial COX-2 expression in mares.
abstract: The objectives were to: (1) evaluate the efficacy of varying intervals of oxytocin administration in preventing luteolysis in mares; (2) examine PGF(2α) release in mares experiencing prolonged diestrus secondary to oxytocin treatment; and (3) evaluate the endometrial expression of oxytocin receptor, estrogen receptor α, and prostaglandin synthesis enzymes after oxytocin administration. In experiment I, mares received oxytocin (60 IU, im) daily on Days 8 to 10, 8 to 12, or 8 to 14 postovulation, and control mares received sterile saline. Prolongation of diestrus was defined by elevation of serum progesterone >1.0 ng/mL through Day 30 postovulation. The proportion of mares experiencing prolonged cycles increased (P < 0.01) as the number of days of oxytocin administration increased. Oxytocin administration on Days 8 to 10, 8 to 12, and 8 to 14 prolonged luteal maintenance in 3/7, 4/7, and 6/7 mares respectively, compared with 0/7 control mares. Treated mares with prolonged diestrus had lower (P < 0.05) plasma PGFM concentrations at Day 16 than did mares with normal diestrus periods. In experiment II, endometrial biopsies from mares treated with oxytocin from Days 8 to 14 postovulation (N = 6) had reduced cyclooxygenase-2 expression (P < 0.05) compared with control mares (N = 6) as determined by quantitative reverse transcription polymerase chain reaction and immunohistochemical staining. Oxytocin administration prolonged luteal maintenance in mares, with an increasing number of mares responding to treatment as the number of days of oxytocin administration was increased beyond Day 8 postovulation. Luteal maintenance in mares was also associated with decreased plasma PGFM concentrations and reduced endometrial cyclooxygenase-2 expression.
authors.affiliation: Gluck Equine Research Center, Department of Veterinary Science, University of Kentucky, Lexington, Kentucky, USA.
authors.forename: L
authors.initials: L
authors.lastname: Keith
authors.forename: B A
authors.initials: BA
authors.lastname: Ball
authors.forename: K
authors.initials: K
authors.lastname: Scoggin
authors.forename: A
authors.initials: A
authors.lastname: Esteller-Vico
authors.forename: E M
authors.initials: EM
authors.lastname: Woodward
authors.forename: M H T
authors.initials: MH
authors.lastname: Troedsson
authors.forename: E L
authors.initials: EL
authors.lastname: Squires
mesh_terms: D000818:Animals; D003338:Corpus Luteum / Q000187:drug effects / Q000502:physiology*; D051546:Cyclooxygenase 2 / Q000235:genetics*; D004031:Diestrus / Q000187:drug effects*; D015237:Dinoprost / Q000031:analogs & derivatives / Q000097:blood; D004717:Endometrium / Q000201:enzymology*; D005260:Female; D015870:Gene Expression / Q000187:drug effects; D006736:Horses / Q000502:physiology*; D007150:Immunohistochemistry / Q000662:veterinary; D003341:Luteolysis / Q000187:drug effects; D010060:Ovulation / Q000502:physiology; D010121:Oxytocin / Q000008:administration & dosage*; D011374:Progesterone / Q000097:blood; D012333:RNA, Messenger / Q000032:analysis; D018045:Receptors, Oxytocin / Q000032:analysis / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000662:veterinary
chemical_list: D012333:RNA, Messenger; D018045:Receptors, Oxytocin; C008228:15-keto-13,14-dihydroprostaglandin F2alpha; D011374:Progesterone; D010121:Oxytocin; D015237:Dinoprost; D051546:Cyclooxygenase 2